Today, Fagron acquired Letco Medical. Letco is a supplier of pharmaceutical raw materials, supplies and equipment for compounding in the USA with expected sales of approximately US$ 40 million and an expected EBITDA margin of around 11% in 2021. The acquisition price is US$ 34 million.
Letco Medical, LLC (Letco Med), is pleased to announce it has entered an exclusive partnership with CBD industry leader, Fourth Power Labs, to sell its products to the independent compounding pharmacy marketplace. This new partnership enables Letco Med to offer the highest quality, broad spectrum THC-free products on the market today to customers in support of their patients' wellness regimens. Fourth Power Labs products, available only to Medical Professionals, can now be purchased through Letco Med's dedicated salesforce and online at www.letcomed.com.
Letco Medical, LLC (Letco Med), is pleased to announce its three-year financial commitment of over $100,000 to fund the Alliance for Pharmacy Compounding (APC) nationwide advocacy campaign. This effort is focused on protecting patient access to compounded bioidentical hormone therapies (cBHT) that millions of Americans depend on and safely use every day. Additionally, Letco announces a new partnership program with its customers to further fund and support APC's patient advocacy initiatives and efforts.